Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Buys 5,030 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela purchased 5,030 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were bought at an average cost of $5.03 per share, with a total value of $25,300.90. Following the purchase, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at approximately $2,209,422.47. This represents a 1.16 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI remained flat at $5.11 on Friday. 61,315 shares of the company’s stock traded hands, compared to its average volume of 28,061. The business has a 50-day moving average of $4.59 and a two-hundred day moving average of $4.75. TriSalus Life Sciences, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The company has a market capitalization of $155.80 million, a PE ratio of -2.05 and a beta of 0.51.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of recent research reports. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Roth Mkm reissued a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.79.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of TLSI. Geode Capital Management LLC grew its holdings in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at $184,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at $108,000. Virtu Financial LLC purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at $92,000. Finally, Walleye Capital LLC purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at $66,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.